

General Information**Perner, Florian, Dr. med., Date of birth: June 25th, 1990**

Hannover Medical School, Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation

(e) f.perner@gmail.com;

(ph) +49-151 59980628

Position: Junior Research Group leader, physician

Academic Education**10/09-11/16** Medical School, Otto-von-Guericke University Magdeburg, Germany**Scientific and Academic Degrees****11/18** Doctoral Thesis (Dr. med.), Otto-von-Guericke University Magdeburg, (Supervisor: Prof. T. Fischer), summa cum laude**11/16** Approbation / State Exam**Professional Career****since 2024** Emmy-Noether Research Group Leader "Translational Epigenetics" at Hannover Medical School, Germany**2022-2024** Junior Research Group leader, Internal Medicine C, University Medicine Greifswald, Germany**2018-2022** Post-Doctoral Research Fellow, Dana Farber Cancer Institute, Harvard University, Boston, USA (Laboratory of Prof. S. A. Armstrong, MD, PhD)**2016-2018** Associate Scientist, Leibniz Institute on Aging, Jena, Germany**2017-2018** Residency/Fellowship (Internal Medicine & Hematology/Oncology), Friedrich Schiller University Jena, Germany**Stipends and research programs****since 2024** Funding by the "Emmy-Noether Programme", Excellence program of the German Research Foundation (DFG)**06/20-06/22** Postdoctoral Research Fellowship by the German Research Foundation (DFG)**06/18-06/19** Momentum Fellowship Award recipient of the Mark Foundation for Cancer Research**05/17-05/18** Member of the physician scientist program within the "Interdisciplinary Center for Clinical Research" (IZKF), Friedrich Schiller University Jena, Germany**04/12-04/16** Member of the graduate school training program GRK1167 by the German Research Foundation (DFG), Otto-von-Guericke University Magdeburg, Germany.**Prices and Awards****10/2023** Recipient of the 2023 Artur-Pappenheim Price by the German Society for Hematology and Oncology**Professional Memberships****since 2022** Member of the American Society of Hematology (ASH)**since 2023** Member of the European Hematology Association (EHA)**since 2023** Member of the German Society for Hematology and Oncology**Publications (10 selected of last 5 years)****Perner F.**, Stein E.M., Wenge D.V., Singh S., Kim J., Apazidis A., Rahnamoun H., Anand D., Marinaccio C., Hatton C., Wen Y., Stone R.M., Schaller D., Mowla S., Xiao W., Gamlen H.A., Stonestrom A.J., Persaud S., Ener E., Cutler J.A., Doench J.G., McGeehan G.M., Volkamer A., Chodera J.D., Nowak R.P., Fischer E.S., Levine R.L., Armstrong S.A., Cai S.F. MEN1 mutations mediate clinical resistance to Menin inhibition. 2023. *Nature*. 615(7954):913-919.Soto-Feliciano Y.M.*, Sánchez-Rivera F.J.*, **Perner F.***, Barrows D.W., Kastenhuber E.R., Ho Y.J., Carroll T., Xiong Y., Anand D., Soshnev A., Gates L., Beytagh M.C., Cheon D., Gu S., Liu X.S., Krivtsov A.V., Meneses M., de Stanchina E., Stone R.M., Armstrong S.A., Lowe S.W., and Allis C.D. A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition. 2023. *Cancer Discovery*, 13(1): p. 146-169. * **authors contributed equally****Perner F.**, Schnoeder T.M., Xiong Y., Jayavelu A.K., Mashamba N., Tubio Santamaria N., Huber N., Todorova K., Hatton C., Perner B., Eifert T., Murphy C., Hartmann M., Hoell J.I., Schröder N., Brandt S., Hochhaus A., Mertens P.R., Mann M., Armstrong S.A., Mandinova A., Heide F.H. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. 2021. *Leukemia*; in print

Perner F., Gadrey J.Y., Xiong Y., Hatton C., Eschle B.K., Weiss A., Stauffer F., Gaul C., Tiedt R., Perry J.A., Armstrong S.A., & Krivtsov A.V. Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts. 2020. **Blood**. doi:10.1182

Aubrey B.A., Cutler B.J., Bourgeois W., Donovan K.A., Gu S., Hatton C., Perlee S., **Perner F.**, Rahnamoun H., Theall A.C.P., Henrich J.A., Zhu Q., Nowak R.P., Kim Y.J., Parvin S., Cremer A., Olsen S.N., Eleuteri N.A., Pikman Y., McGeehan G.M., Stegmaier K., Letai A., Fischer E.S., Liu X.S., & Armstrong S.A., IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. 2022. **Nature Cancer**, 3(5): p. 595-613.

Uckelmann H.J., Haarer E.L., Takeda R., Wong E.M., Hatton C., Marinaccio C., **Perner F.**, Rajput M., Antonissen N.J.C., Wen Y., Yang L., Brunetti L., Chen C.W. & Armstrong S.A.. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. 2022. **Cancer Discovery**, CD-22-0366

Olsen S.N., Godfrey L., Healy J.P., Choi Y.A., Kai Y., Hatton C., **Perner F.**, Haarer E.L., Nabet B., Yuan G.C. & Armstrong SA. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. 2022. **Molecular Cell**, 82(6): p. 1140-1155 e11.

Heikamp E.B., Henrich J.A., **Perner F.**, Wong E.M., Hatton C., Wen Y., Barwe S.P., Gopalakrishnapillai A., Xu H., Uckelmann H.J., Takao S., Kazansky Y., Pikman Y., McGeehan G.M., Kolb E.A., Kentsis A. & Armstrong S.A. The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. 2022. **Blood**. 139(6):894-906

Jayavelu, A.K., Schnoeder, T.M., **Perner, F.**, Herzog, C., Meiler, A., Krishnamoorthy, G., Huber, N., Mohr, J., Edelmann-Stephan, B., Austin, R., Brandt, S., Palandri, F., Schroder, N., Isermann, B., Edlich, F., Sinha, A.U., Ungelenk, M., Hubner, C.A., Zeiser, R., Rahmig, S., Waskow, C., Coldham, I., Ernst, T., Hochhaus, A., Jilg, S., Jost, P. J., Mullally, A., Bullinger, L., Mertens, P.R., Lane, S.W., Mann, M., & Heide, F.H. (2020). Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. **Nature**, 588(7836), 157-163.

Krivtsov, A.V., Evans, K., Gadrey, J.Y., Eschle, B.K., Hatton, C., Uckelmann, H.J., Ross, K.N., **Perner, F.**, Olsen, S.N., Pritchard, T., McDermott, L., Jones, C.D., Jing, D., Braytee, A., Chacon, D., Earley, E., McKeever, B.M., Claremon, D., Gifford, A.J., Lee, H.J., Teicher, B.A., Pimanda, J.E., Beck, D., Perry, J.A., Smith, M.A., McGeehan, G.M., Lock, R.B., & Armstrong, S.A. (2019). A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. **Cancer Cell**, 36(6), 660-673